Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06KJQ
|
|||
Former ID |
DCL001157
|
|||
Drug Name |
BI 201335
|
|||
Synonyms |
Faldaprevir; BI-201335; UNII-958X4J301A; CHEMBL1241348; 958X4J301A; N-[(Cyclopentyloxy)carbonyl]-3-Methyl-L-Valyl-(4r)-4-[(8-Bromo-7-Methoxy-2-{2-[(2-Methylpropanoyl)amino]-1,3-Thiazol-4-Yl}quinolin-4-Yl)oxy]-N-[(1r,2s)-1-Carboxy-2-Ethenylcyclopropyl]-L-Prolinamide; BI 201335; 801283-95-4; BI201335; Faldaprevir [USAN:INN]; SCHEMBL222429; BDBM50336545; SB16712; DB11808
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 3 | [1] | |
Company |
Boehringer Ingelheim Pharma
|
|||
Structure |
Download2D MOL |
|||
Formula |
C40H49BrN6O9S
|
|||
Canonical SMILES |
CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)OC4CC(N(C4)C(=O)C(C(C)(C)C)NC(=O)OC5CCCC5)C(=O)NC6(CC6C=C)C(=O)O
|
|||
InChI |
1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
|
|||
InChIKey |
LLGDPTDZOVKFDU-XUHJSTDZSA-N
|
|||
CAS Number |
CAS 801283-95-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Drug Resistance Mutation (DRM) | Top | |||
---|---|---|---|---|
DRM | DRM Info |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | 2011 Pipeline of Boehringer Ingelheim Pharma. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.